Rabies Advice Centre
Since 2005, the Rabies Advisory Centre has been providing advice on all matters relating to rabies. Our medical team is available to doctors and patients 365 days a year.
The advisory services include, in particular:
- Information on the rabies situation in Austria and abroad
- Assessment of potential rabies exposure and advice on post-exposure prophylaxis (PEP)
In addition, the Rabies Advisory Centre produces an annual report.
Testing for antibody titres against the rabies virus (human diagnostics) is offered by the AGES Institute for Medical Microbiology and Hygiene in Vienna.
Rabies vaccines, immunoglobulin and vaccination centres
Rabipur® and Verorab® are available in Austria for active immunisation. Berirab® is used for passive immunisation. Information on current availability and professional information can be found on the BASG portal ‘Medikamente Info Austria’.
Post-exposure prophylaxis (PEP) is available free of charge in Austria at the rabies vaccination centres designated by the Federal Ministry of Labour, Social Affairs, Health, Care and Consumer Protection (BMASGPK).
Further information: List of rabies vaccination centres for PEP
FAQ: Rabies
Active immunisation involves the use of inactivated rabies vaccines. Following administration, the body is stimulated to produce antibodies against the rabies virus. Active immunisation is used as part of pre-exposure prophylaxis (before potential exposure to rabies, e.g. as a travel vaccination) and as part of post-exposure prophylaxis (after exposure to rabies has occurred).
In contrast, the administration of rabies antibodies (also known as ‘human rabies immunoglobulin’ [HRIG]) is a form of passive immunisation, in which antibodies against the rabies virus are administered directly to the patient. The aim of passive immunisation is to bridge the time until the body’s own antibodies are produced following the administration of active immunisation. Unlike active immunisation, passive immunisation is only indicated in specific situations following exposure to a risk of rabies, as part of post-exposure prophylaxis.
As part of active immunisation, inactivated rabies vaccines are used both for pre-exposure prophylaxis (prior to potential exposure to rabies, e.g. as a travel vaccination) and for post-exposure prophylaxis (following a rabies exposure). Nowadays, these are in most cases so-called cell-culture vaccines, in which rabies viruses are grown on human or animal cells and subsequently inactivated. Cell-culture vaccines have replaced the nerve tissue vaccines that were previously in use.
In Austria, two inactivated rabies vaccines are available: the Rabipur® vaccine, a cell-culture vaccine based on chicken embryo cells, and Verorab®, a cell-culture vaccine based on Vero cells. For passive immunisation, the human rabies immunoglobulin Berirab® is available in Austria.
The safety profile of commercially available rabies vaccines is considered excellent; vaccine reactions such as local reactions at the injection site, headaches, tiredness, a general feeling of being unwell, fever and dizziness are possible, but are short-lived. All known possible side effects are also listed in the relevant product information for the vaccine being used, along with details of the approximate frequency with which they may occur. Information on possible side effects, interactions and contraindications can also be provided by the treating doctor.
If there is a known risk of a severe allergic reaction to the vaccine or any of its components, a different rabies vaccine that does not contain that component may be administered. This is an individual decision that must be made on a case-by-case basis by the treating doctor.
An allergy to chicken egg white does not constitute an absolute contraindication to the administration of the chicken egg white-containing vaccine Rabipur®. Should an alternative, chicken-egg-white-free preparation nevertheless be chosen, options include, for example, the Verorab® rabies vaccine produced in Vero cells or the HDC rabies vaccine produced in human diploid cells. As the HDC rabies vaccine is not available in Austria, it must be obtained from abroad if necessary, for example via the Internationale Apotheke (Kärntner Ring 17, 1010 Vienna, +43 1 5122825).
Both active and passive immunisation (inactivated rabies vaccine and immunoglobulin, respectively) have been shown to be safe and effective during pregnancy and whilst breastfeeding. Particularly given the severity of rabies infection and the lack of treatment options for the disease, post-exposure prophylaxis must be administered in accordance with the category of exposure following a rabies risk exposure, even during pregnancy and breastfeeding. In the case of pre-exposure prophylaxis (prior to potential exposure to rabies, e.g. as a travel vaccination), an individual risk-benefit assessment must be carried out in consultation with the treating doctor.
The same preparations are used for both children and adults in the context of both active and passive immunisation (inactivated rabies vaccine and immunoglobulin respectively). There are no specific rabies vaccines for children. Further information can be found in the product information leaflets for the respective products (Rabipur®, Verorab®, Berirab®).
Where possible, the same vaccine should be used for the primary vaccination course. This also applies to the vaccination series administered as part of post-exposure prophylaxis.
In principle, all modern cell-culture rabies vaccines are interchangeable; however, switching vaccines constitutes off-label use. If such a change is unavoidable (e.g. due to vaccine supply shortages or because post-exposure prophylaxis was started abroad with a different vaccine and continued in Austria), this may be carried out following a careful risk-benefit assessment and after the patient has been informed about the off-label use.
In the event of a change of vaccine, it is in any case important that the relevant vaccination schedule is maintained.
Vaccines commonly used in other countries that are compatible with Rabipur® or Verorab® include, for example, HDC vaccines (Human Diploid Cell Culture Rabies Vaccine, HDCV) or PDE vaccines (Purified Duck Embryo Vaccine, PDEV).
Vaccines based on nervous tissue (e.g. Suckling Mouse Brain Vaccine, SMBV) are not compatible; however, their production is being phased out due to an unfavourable side-effect profile and a comparatively poor immune response.
Pre-exposure rabies vaccination is recommended for people before travelling to an area where rabies is endemic. In particular, travellers who plan to undertake outdoor activities (e.g. cycling, hiking) in areas where rabies is endemic, or who are travelling to remote areas where prompt medical care cannot be guaranteed, should receive a course of vaccinations before departure.
For stays in Austria, pre-exposure rabies vaccination is recommended only for people who may be occupationally exposed to rabies. This includes staff in the fields of veterinary medicine and animal care (including veterinary students, taxidermists, animal keepers, animal traders), the military or emergency services, epidemiology, relevant laboratories and vaccine production facilities, as well as bat researchers and cavers. For hunters and those working in forestry and agriculture, rabies prophylaxis is only indicated during (hunting) trips to countries where rabies is endemic or in areas bordering such endemic regions.
- Conventional schedule: one dose (0.5 or 1 ml intramuscularly, depending on the manufacturer’s instructions) on days 0, 7 and 21–28 (for all age groups).
- Accelerated schedule: one dose (0.5 or 1 ml intramuscularly, depending on the manufacturer’s instructions) on days 0, 3 and 7 (for immunocompetent individuals aged between 18 and 65, if the conventional schedule cannot be followed due to time constraints; for Verorab® off-label use).
- Alternative accelerated schedule: one dose (0.5 or 1 ml intramuscularly, depending on the manufacturer’s instructions) on days 0 and 7 (only for immunocompetent individuals; for Rabipur® off-label). According to the Austrian Immunisation Schedule, it is recommended that the primary course of vaccination be completed with a third dose after one year if future travel to areas where rabies is endemic cannot be ruled out.
Due to the often limited availability of rabies immunoglobulin in some areas where rabies is endemic, the Austrian Immunisation Schedule recommends that travellers, where indicated, should in any case receive at least a single intramuscular dose prior to departure (off-label use).
According to the Austrian Immunisation Schedule, in exceptional cases (e.g. in the event of a vaccine shortage), the vaccine may be administered intradermally instead of intramuscularly. Under both the conventional schedule and the accelerated schedule, 0.1 ml is administered intradermally on each of the three days (off-label). Under the alternative accelerated schedule, two doses of 0.1 ml each are administered intradermally on days 0 and 7 (one in the left arm and one in the right arm) (off-label for Rabipur®).
However, the correct administration of the vaccine intradermally requires practice and should therefore only be used in exceptional cases. When administered correctly, an immune response equally as good as that achieved with intramuscular administration can be expected.
Immunosuppressed individuals should, in any case, be vaccinated as part of a pre-exposure prophylaxis regime consisting of three doses (conventional schedule: days 0, 7 and 21–28). In addition, a follow-up test (determination of antibody titre using a neutralisation test) should be carried out 2–4 weeks after the third dose to assess the need for further doses.
According to the WHO, routine booster vaccinations are not required for the general population once the primary vaccination course has been fully completed. The primary immunisation induces long-lasting immunological memory and thus a booster response that has been demonstrated to last for decades. This means that the post-exposure booster vaccinations required following exposure to rabies trigger a rapid immune response even if the primary immunisation took place a long time ago.
However, as a precaution, people travelling to areas where rabies is endemic and where vaccine availability is poor should have a contact-independent booster vaccination before departure, provided that their primary immunisation took place more than 2–5 years ago. Furthermore, individuals exposed to an ongoing risk of rabies (e.g. those exposed in the course of their work) should have their antibody levels tested or receive a booster vaccination every 2–5 years.
People who, due to their occupation, are exposed to an ongoing risk of rabies should have their rabies antibody levels checked (titre tests) every 2–5 years. If titer checks are not possible, a booster vaccination may alternatively be administered every 2–5 years, regardless of antibody levels.
In individuals with immunosuppression, a check of antibody levels is also indicated (both following primary immunisation and after post-exposure prophylaxis) in order to assess the need for additional vaccine doses.
Post-exposure rabies prophylaxis refers to measures designed to prevent rabies following a high-risk exposure to the virus. Essentially, post-exposure rabies prophylaxis consists of three pillars: wound care, active immunisation and passive immunisation. The measures required depend on an individual risk assessment, taking into account the nature of the contact, the species of animal, the rabies situation in the area of exposure, and the vaccination and immune status of the person concerned.
When assessing whether post-exposure rabies prophylaxis is required following contact with an animal, the following aspects in particular must be taken into account:
- Country of exposure
- Species of animal
- Type of contact
Classification into WHO exposure categories I–III is based on the nature of the contact (see Table 1). Recommendations for post-exposure rabies prophylaxis are based on the exposure category and an individual risk assessment, taking into account the vaccination and immune status of the person concerned.
Table 1: Indications for post-exposure prophylaxis by exposure category for immunocompetent individuals
| Exposure category | Type of contact with a mammal suspected of having rabies | Recommendations for post-exposure prophylaxis (PEP) |
| I | Touching or feeding animals Bats: Contact/bite/scratch/abrasion can be ruled out. The mere presence of a bat in the same room does not constitute suspected rabies exposure. | No PEP (if medical history is reliable) Cleaning of exposed skin areas |
| II | Nibbling at uncovered skin Bats: Direct contact/touch without a perceived, but not definitively ruled out, bite/scratch/abrasion/mucosal contact with saliva2 | PEP with
PEP may be terminated early if:
|
| III | Transdermal bite wounds or scratches Bats: Direct contact with a perceived bite/scratch/abrasion/mucosal contact with saliva2 | PEP with
PEP may be terminated early if:
|
1 Not applicable to individuals who have
previously received at least two vaccinations (e.g. as part of the primary immunisation course) 2 Modified in accordance with the Austrian Immunisation Schedule
Following exposure to a potential rabies risk, wounds (bite wounds, scratches) should be washed and rinsed thoroughly with plenty of soap and water for 15 minutes. A virucidal antiseptic (e.g. povidone-iodine) should then be applied. This mechanically removes or inactivates viruses at the wound site, thereby reducing the risk of infection.
The need for further measures (e.g. trauma surgery, antibiotic or analgesic treatment, and a tetanus vaccination) should be assessed by the attending doctor.
Active immunisation as part of post-exposure rabies prophylaxis refers to the administration of inactivated rabies vaccines following exposure to a risk of rabies. The vaccination stimulates the body to produce specific antibodies against the rabies virus. These antibodies can neutralise the virus, thereby preventing it from penetrating nerve cells and reaching the central nervous system. Thus, if post-exposure prophylaxis is administered in good time and carried out correctly, the onset of rabies can be prevented.
Passive immunisation as part of post-exposure rabies prophylaxis refers to the administration of ready-made antibodies against the rabies virus; in Austria, this takes the form of human rabies immunoglobulin (HRIG). These antibodies can neutralise the virus immediately at the site of entry and bridge the gap until the body’s own antibodies are produced following active immunisation. Passive immunisation is carried out in addition to active immunisation where indicated. It is particularly necessary for previously unvaccinated individuals following Category III exposure. Special recommendations apply to immunocompromised individuals.
The number of vaccine doses required depends on the individual’s previous rabies vaccination history and their immune status. The following information relates to intramuscular vaccination in immunocompetent individuals. Day 0 refers to the day of the first vaccination as part of the current PEP, not necessarily the day of the exposure.
For individuals who have been fully vaccinated previously, two doses are administered: one on day 0 and one on day 3 (= shortened PEP regimen). This also applies if the primary vaccination took place a long time ago. A previous post-exposure vaccination series may also be considered sufficient prior immunisation. The vaccinations recognised for this purpose are described in the next question.
For individuals who have not been vaccinated or who have received an incomplete course of vaccination, a full PEP regimen is required. The following intramuscular regimens are available for this purpose:
- Classic Essen regimen: one dose on each of days 0, 3, 7, 14 and 28 – a total of five doses
- Zagreb regimen: two doses on day 0 at different injection sites, usually one on each of the right and left upper arms, and one dose each on days 7 and 21 – a total of four doses.
However, according to the recommendations of the World Health Organisation (WHO), the fifth dose on day 28 under the Essen schedule may be omitted for healthy, immunocompetent individuals.
Special recommendations apply to immunocompromised individuals.
People who have been immunised according to the following schedules are considered to be fully vaccinated:
- Conventional schedule with three doses (on days 0, 7, 21–28)
- Accelerated schedule with three doses (on days 0, 3 and 7)
- Alternative accelerated schedule with two doses (on days 0 and 7)
- Within one year of the second dose: individuals are considered to have completed their primary vaccination course
- More than one year after the second dose: individuals are only considered to have completed their primary vaccination series if a third dose has been administered after one year to complete the primary vaccination series
- Post-exposure prophylaxis with at least three of the five vaccinations in the Essen regimen or with a complete Zagreb regimen
Passive immunisation (administration of rabies immunoglobulin) should always be carried out following a Category III rabies exposure. In addition, immunocompromised individuals should also receive passive immunisation following a Category II rabies exposure.
In the case of immunocompetent individuals who have previously received at least two doses of a rabies vaccine, immunoglobulin is no longer administered following a suspected rabies exposure, regardless of the category of exposure.
If post-exposure prophylaxis is to be administered retrospectively following an exposure that occurred some time ago, in the case of an exposure that occurred more than one year ago, only active immunisation is carried out – and not passive immunisation – even if there is a corresponding indication.
Where possible, the immunoglobulin should be administered on the same day as the first vaccination. Administration may be carried out up to and including the seventh day after the start of active immunisation.
The recommended vaccination intervals for post-exposure rabies prophylaxis should be adhered to as closely as possible. If a dose is missed, it should be administered as soon as possible. The vaccination course is then continued, maintaining the intervals between the remaining doses as specified for the relevant schedule.
Post-exposure rabies prophylaxis should be initiated immediately following exposure to a potential source of rabies, provided there is a corresponding indication. As incubation periods of over a year have been reported in rare cases, post-exposure prophylaxis (PEP) is still indicated following an individual risk assessment, even for exposures that occurred months or years ago, provided that no symptoms consistent with rabies have developed.
As there is no effective treatment available for active rabies, the timely administration of post-exposure prophylaxis (PEP) is of crucial importance. Where indicated, PEP must therefore be started immediately. In particular, the start of PEP must not be delayed until the results of a rabies test on the animal are available.
Following a high-risk exposure to rabies involving a dog or cat, post-exposure prophylaxis (PEP) that has already been started may be discontinued early if the animal has remained healthy during a ten-day observation period following the exposure.
Regardless of the species of animal, PEP that has already been started may also be discontinued if a post-mortem examination of the animal in question, carried out professionally using recognised diagnostic methods, has yielded a reliable negative result for rabies.
In immunocompetent individuals, following renewed exposure to the risk of rabies within three months of completing a full course of post-exposure prophylaxis in accordance with WHO guidelines, no further active or passive immunisation is required. Appropriate wound care should nevertheless be provided. Separate recommendations apply to immunocompromised individuals.
In immunocompromised individuals, post-exposure prophylaxis consisting of active immunisation (the full Essen schedule comprising 5 vaccinations on days 0, 3, 7, 14 and 28; an additional dose may be administered on day 0) and passive immunisation with human rabies immunoglobulin (HRIG). This also applies to individuals who have previously completed their primary immunisation course. The specific procedure must be determined in accordance with the current Austrian Immunisation Schedule, taking into account the type and extent of immunosuppression, and in consultation with a specialist medical centre.
As the immune response may be reduced in cases of immunosuppression, the success of the vaccination should be monitored by measuring neutralising antibodies. The timing and further course of action should be agreed at an early stage with a specialist medical centre. If a titre of at least 0.5 IU/ml is not achieved, additional vaccine doses and repeat serological tests are required, as determined by a specialist.
In Austria, post-exposure rabies prophylaxis (active and passive immunisation) is provided free of charge by the designated national rabies vaccination centres.
- Federal Ministry of Labour, Social Affairs, Health, Care and Consumer Protection (BMASGPK). Austrian Immunisation Schedule 2026/2027. Version 1.1 (as at 14 October 2026). Vienna: BMASGPK; 2026.
- World Health Organisation (WHO): Rabies. Available online at: https://www.who.int/en/news-room/fact-sheets/detail/rabies (last accessed on: 20 October 2026).
- Robert Koch Institute (2026): Rabies. RKI Guide. Available online at: https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Tollwut.html (last accessed: 20 October 2026).
- World Health Organisation (WHO). Rabies Vaccines: WHO Position Paper – April 2018. 2018. Weekly Epidemiological Record, No. 16, 2018, 93, 201–220.
- Jackson A, Wunner W. Rabies. Scientific Basis of the Disease and Its Management. 2nd edition. London: Academic Press; 2007.
- Russell K, Brown K. UKHSA guidelines on managing rabies post-exposure (January 2023). UK Health Security Agency; 2023.
- World Health Organisation. FAQs: Frequently asked questions on rabies. WHO Regional Office for South-East Asia. New Delhi: WHO; 2013.
- Fitzpatrick JL, Dyer JL, Blanton JD, Kuzmin IV, Rupprecht CE. Rabies in rodents and lagomorphs in the United States, 1995–2010. J Am Vet Med Assoc. 2014;245(3):333–7.
- Standing Committee on Vaccination, German Society for Tropical Medicine. Epidemiological Bulletin 27/2026. Recommendations of the Standing Committee on Vaccination (STIKO) and the German Society for Tropical Medicine, Travel Medicine and Global Health (DTG) on travel vaccinations. Berlin: RKI; 2026.
- WHO Expert Consultation on Rabies, third report. Geneva: World Health Organisation; 2018 (WHO Technical Report Series, No. 1012). Licence: CC BY-NC-SA 3.0 IGO.
- Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunisation Practices. MMWR Recomm Rep. 2008;57(Rr-3):1–28.
- Roß RS. Rabies prophylaxis: how to advise patients in general practice. MMW – Advances in Medicine. 2020;162(11):53–8.
- Weißer K, Barth I, Keller-Stanislawski B. Vaccine safety. Federal Health Gazette – Health Research – Health Protection. 2009;52(11):1053–64.
- Bavarian Nordic A/S. Product information for Rabipur: powder and solvent for the preparation of a solution for injection in a pre-filled syringe. Hellerup, Denmark: Bavarian Nordic A/S; as at March 2026. Available online at: https://medikamente.basg.gv.at/documents/237614__DOTC_FACH_INFO.pdf (last accessed: 20 October 2026)
- Ravish HS, Sudarshan MK, Madhusudana SN, Annadani RR, Narayana DH, Belludi AY, et al. Assessing the safety and immunogenicity of post-exposure prophylaxis following the interchangeability of rabies vaccines in humans. Hum Vaccin Immunother. 2014;10(5):1354–8.
- Tepsumethanon V, Lumlertdacha B, Mitmoonpitak C, Sitprija V, Meslin FX, Wilde H. Survival of naturally infected rabid dogs and cats. Clin Infect Dis. 2004;39(2):278–80.
- Federal Ministry of Social Affairs, Health, Care and Consumer Protection (BMSGPK). Vaccinations in cases of allergies. Version 2.0, 23 May 2022. Vienna: BMSGPK; 2022.
- Sanofi. Verorab. Powder and solvent for the preparation of a suspension for injection. Rabies vaccine, inactivated. Product information. Gentilly, France: Sanofi Winthrop Industrie; 2025. Available online at: https://medikamente.basg.gv.at/documents/241712__DOTC_FACH_INFO.pdf (last accessed on: 20 October 2026).
Contact and further information
Wien Währingerstraße
- +43 50 555 37111
- +43 50 555-37109
-
Währingerstraße 25a
1090 Wien
Die Tollwutberatungsstelle ist zu folgenden Zeiten unter folgenden Nummern erreichbar:
Montag bis Donnerstag 8:00 bis 16:00 Uhr, Freitag 8:00 bis 14:00 Uhr:
+43 (0) 50555-37111
Restliche Zeit (rund um die Uhr):
+43 (0) 50555-38112
Die Zuständigkeit der Beratungsstelle gilt ausschließlich für Österreich und kann nur von Personen in Anspruch genommen werden, die in Österreich leben, sich vorübergehend in Österreich aufhalten oder sich in Österreich allenfalls infiziert haben. Empfehlungen anderer Länder können sich von österreichischen Leitlinien unterscheiden. Wir weisen darauf hin, dass die Beratung durch die Tollwutberatungsstelle ausschließlich der Information dient und weder die ärztliche Diagnose noch die ärztliche Behandlung ersetzt.
Last updated: 17.11.2026
automatically translated